Immune Checkpoints Indoleamine 2,3-Dioxygenase 1 and Programmed Death-Ligand 1 in Oral Mucosal Dysplasia

Sieviläinen, Meri; Passador-Santos, Fabrício; Almahmoudi, Rabeia; Christopher, Solomon; Siponen, Maria; Toppila‐Salmi, Sanna; Salo, Tuula; Al‐Samadi, Ahmed

doi:10.1016/j.oooo.2019.02.028

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they did not find any PD‐L1 expression within the epithelium. The PD‐L1 expression in the lamina propria fluctuated over time and was not reliable to monitor dysplasia progression (Sieviläinen et al, ). PD‐L1 has also been investigated in oral lichen planus.…”

Section: Clinical Implications Of Pd‐l1 Expression In Oral Potentiallmentioning

confidence: 99%

An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives

et al. 2019

View full text Add to dashboard Cite

Programmed cell death‐ligand 1 (PD‐L1) is a transmembrane protein that acts as a co‐inhibitory factor in the immune response. Its receptor, programmed cell death protein 1 (PD‐1), is found on immune cells, where binding to PD‐L1 can reduce the proliferation of PD‐1‐positive cells, inhibit their cytokine secretion and induce apoptosis. PD‐L1 in immune‐privileged tissue plays a crucial role in peripheral tolerance. PD‐L1 can be overexpressed in various malignancies, including oral squamous cell carcinoma, where it can attenuate the host immune response to tumour cells and has been associated with a worse prognosis. Monoclonal antibody therapies targeting the PD‐1:PD‐L1 axis have shown initial promise, but further research is needed to identify which patients will benefit. We provide an update of knowledge on PD‐L1, including its structure, function and regulation. We also review studies on the overexpression of PD‐L1 in cancer, specifically oral squamous cell carcinoma, and explore its potential value as a therapeutic target.

show abstract

Section: Clinical Implications Of Pd‐l1 Expression In Oral Potentiallmentioning

confidence: 99%

An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Whilst it may be coincidental, it is possible that inflammation is a common factor in these two disease processes. It is well documented that inflammatory mediators play a role in the drive of OED 44,45 and progression to malignancy 46,47 . For example, overexpression of the inflammatory cytokine tumour necrosis factor (TNF‐β) is associated with malignant transformation 48 of OED and an increase in mast cell production in dysplastic lesions is thought to be associated with angiogenesis 49 .…”

Section: Discussionmentioning

confidence: 99%

Localised oral amyloidosis in the context of oral epithelial dysplasia: Literature review and report of two cases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations that are frequently characterized as architectural and cytological derangements upon histological analysis (1)(2)(3). OP-MDs exhibit an increased risk of malignant transformation.…”

Section: Introductionmentioning

confidence: 99%

“…A recent meta-analysis estimated an overall risk of malignant transformation of 10.5% for oral epithelial dysplasia (4). The potential of malignant transformation is believed to be related to the degree of epithelial dysplasia observed (2)(3)(4). Several studies have been conducted to identify possible markers that can trigger the development of OPMDs as well as predict their progression (2,5,6).…”

Section: Introductionmentioning

confidence: 99%

“…The potential of malignant transformation is believed to be related to the degree of epithelial dysplasia observed (2)(3)(4). Several studies have been conducted to identify possible markers that can trigger the development of OPMDs as well as predict their progression (2,5,6). The epithelial-mesenchymal transition (EMT) is a mechanism frequently dysregulated in cancer (5)(6)(7)(8)(9)(10)12).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of the immunohistochemical detection of epithelial-mesenchymal transition biomarkers in oral epithelial dysplasia: A systematic review

Morais

Pinheiro²,

Lira³

et al. 2020

Med Oral

View full text Add to dashboard Cite

Background: Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations that are frequently characterized as architectural and cytological derangements upon histological analysis. Epithelial-mesenchymal transition (EMT) has been proposed as a critical mechanism for the acquisition of the malignant phenotype in neoplastic epithelial processes. This study aims to systematically review the current findings on the immunohistochemical expression of epithelial-mesenchymal transition markers in oral potentially malignant disorders and to evaluate their possible application as biomarkers associated with the progression of oral epithelial dysplasias. Material and Methods: A systematic search was performed in the following databases: PubMed, EMBASE, Chinese BioMedical Literature Database, and Cochrane Library. Articles that evaluated the relationship between the expression of EMT markers and the degree of oral epithelial dysplasia were selected for the systematic review. The quality of each eligible study was evaluated by independent reviewers that used operationalized prognostic biomarker reporting guidelines (REMARK). Results: Seventeen articles met all inclusion criteria and were selected. The EMT markers analyzed exhibited an important association with the prognosis of the cases evaluated. The results showed a progressive increase in the expression of nuclear transcription factors and markers of mesenchymal differentiation, as well as negative regulation of epithelial and cell adhesion markers, according to the stage of oral epithelial dysplasia.

show abstract

Immune Checkpoints Indoleamine 2,3-Dioxygenase 1 and Programmed Death-Ligand 1 in Oral Mucosal Dysplasia

Cited by 3 publications

References 0 publications

An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives

An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives

Localised oral amyloidosis in the context of oral epithelial dysplasia: Literature review and report of two cases

Prognostic value of the immunohistochemical detection of epithelial-mesenchymal transition biomarkers in oral epithelial dysplasia: A systematic review

Contact Info

Product

Resources

About